Biomarkers in acute cardiac disease: the present and the future.

By Allan S. Jaffe, L. Babuin, F. Apple. Journal of the American College of Cardiology, 2006

689 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Emerging Technologies for Next-Generation Point-of-Care Testing. (2015, neutral): “Direct and indirect biomarkers such as myoglobin, ischemia-modified albumin (IMA), glycogen phosphorylase isoenzyme BB, copeptin (C-terminal proAVP), fatty acid-binding protein (FABP), B-type natriuretic peptide (BNP) (mostly measured as NT-proBNP), and myeloperoxidase have also been identified in a”
Universal definition of myocardial infarction. (2007, methodology): “Troponin values may remain elevated for 7‐14 days following the onset of infarction ( 4 ).”
Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. (2010, methodology): “Our results suggested that the elevated cardiac-specific miRNAs in plasma from AMI patients could be potential biomarkers for the diagnosis of AMI.”
Third universal definition of myocardial infarction. (2012, background): “Although elevations of these biomarkers in the lood reflect injury leading to necrosis of myocardial ells, they do not indicate the underlying mechanism (5).”